Progressive age‐related development of Alzheimer‐like pathology in APP/PS1 mice

Increasing evidence points to synaptic plasticity impairment as one of the first events in Alzheimer's disease (AD). However, studies on synaptic dysfunction in different transgenic AD models that overexpress familial AD mutant forms of amyloid precursor protein (APP) and/or presenilin (PS) have provided conflicting results. Both long‐term potentiation (LTP) and basal synaptic transmission (BST) have been found to be both unchanged and altered in different models and under differing experimental conditions. Because of their more robust amyloid‐β (Aβ) deposition, double transgenic mice currently are used by several laboratories as an AD model. Here, we report that mice overexpressing APP (K670N:M671L) together with PS1 (M146L) have abnormal LTP as early as 3 months of age. Interestingly, reduced LTP paralleled plaque appearance and increased Aβ levels and abnormal short‐term memory (working memory). BST and long‐term memory (reference memory) are impaired only later (approximately 6 months) as amyloid burden increases. Aβ pathology across different ages did not correlate with synaptic and cognitive deficits, suggesting that Aβ levels are not a marker of memory decline. In contrast, progression of LTP impairment correlated with the deterioration of working memory, suggesting that percentage of potentiation might be an indicator of the cognitive decline and disease progression in the APP/PS1 mice. Ann Neurol 2004;55:801–814

[1]  R. Morris,et al.  Place navigation impaired in rats with hippocampal lesions , 1982, Nature.

[2]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[3]  Gary Lynch,et al.  Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice , 1999, Brain Research.

[4]  P. Greengard,et al.  Intraneuronal Abeta42 accumulation in human brain. , 2000, The American journal of pathology.

[5]  Brian J Cummings,et al.  β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.

[6]  G. Collingridge,et al.  Age-Related Impairment of Synaptic Transmission But Normal Long-Term Potentiation in Transgenic Mice that Overexpress the Human APP695SWE Mutant Form of Amyloid Precursor Protein , 2001, The Journal of Neuroscience.

[7]  P. Greengard,et al.  Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .

[8]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[9]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[10]  B. Hyman,et al.  Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. , 2000, The American journal of pathology.

[11]  F. Checler,et al.  Immunohistochemical Analysis of Cerebral Cortical and Vascular Lesions in the Primate Microcebus murinus Reveal Distinct Amyloid β1–42 and β1–40 Immunoreactivity Profiles , 2000, Neurobiology of Disease.

[12]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[14]  D. Linden,et al.  Synaptic transmission and hippocampal long-term potentiation in olfactory cyclic nucleotide-gated channel type 1 null mouse. , 1998, Journal of neurophysiology.

[15]  T. Iwatsubo,et al.  Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). , 1994, Neuron.

[16]  D. Mann,et al.  Diffuse Plaques in the Cerebellum and Corpus Striatum in Down's Syndrome Contain Amyloid β Protein (Aβ) only in the Form of Aβ42(43) , 1996 .

[17]  E. Kandel,et al.  Strain-dependent differences in LTP and hippocampus-dependent memory in inbred mice. , 2000, Learning & memory.

[18]  O. Vitolo,et al.  Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Dickson,et al.  Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes , 1999, Neurobiology of Disease.

[20]  M. Shapiro,et al.  Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein , 1997, Nature.

[21]  D. Mann,et al.  Diffuse plaques in the cerebellum and corpus striatum in Down's syndrome contain amyloid beta protein (A beta) only in the form of A beta 42(43). , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[22]  J. Sweatt,et al.  Accelerated Plaque Accumulation, Associative Learning Deficits, and Up-regulation of α7 Nicotinic Receptor Protein in Transgenic Mice Co-expressing Mutant Human Presenilin 1 and Amyloid Precursor Proteins* , 2002, The Journal of Biological Chemistry.

[23]  H. Tanila,et al.  Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. , 2003, Neuroreport.

[24]  S. Qian,et al.  Transgenic mice expressing the PS1-A246E mutation: effects on spatial learning, exploration, anxiety, and motor coordination , 2003, Behavioural Brain Research.

[25]  D. Borchelt,et al.  An Alzheimer's Disease-Linked PS1 Variant Rescues the Developmental Abnormalities of PS1-Deficient Embryos , 1998, Neuron.

[26]  G. Arendash,et al.  Progressive and gender-dependent cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease , 1999, Behavioural Brain Research.

[27]  N Butters,et al.  Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. , 1992, Archives of neurology.

[28]  H. Cai,et al.  Genetically engineered mouse models of neurodegenerative diseases , 2002, Nature Neuroscience.

[29]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[30]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[31]  Brian J Cummings,et al.  Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. , 1996, Neurobiology of aging.

[32]  C. Kawas,et al.  Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. , 1997, The Journal of clinical investigation.

[33]  N Butters,et al.  Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. , 1991, Archives of neurology.

[34]  T. Iwatsubo,et al.  Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[35]  Gurparkash Singh,et al.  Mutant Human Presenilin 1 Protects presenilin 1 Null Mouse against Embryonic Lethality and Elevates Aβ1–42/43 Expression , 1998, Neuron.

[36]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[37]  G M Rose,et al.  Exposing rats to a predator impairs spatial working memory in the radial arm water maze , 1999, Hippocampus.

[38]  D. Davies,et al.  Neurodegenerative Changes Associated with β-Amyloid Deposition in the Brains of Mice Carrying Mutant Amyloid Precursor Protein and Mutant Presenilin-1 Transgenes , 2001, Experimental Neurology.

[39]  D. Mann,et al.  Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome , 1995, Annals of neurology.

[40]  E. Masliah,et al.  Mechanisms of synaptic dysfunction in Alzheimer's disease. , 1995, Histology and histopathology.

[41]  P. S. St George-Hyslop,et al.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.

[42]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.

[43]  Stephen Maren,et al.  Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. , 2002, Learning & memory.

[44]  J. Roder,et al.  Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes , 2000, Neurobiology of Aging.

[45]  J. Hardy,et al.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.

[46]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[47]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[48]  K. Duff,et al.  Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain , 2000, Neuroscience.

[49]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[50]  O. Arancio,et al.  Usefulness of Behavioral and Electrophysiological Studies in Transgenic Models of Alzheimer's Disease , 2003, Neurochemical Research.

[51]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[52]  T. Bliss,et al.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice , 1999, Nature Neuroscience.

[53]  D. Diamond,et al.  Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes , 2001, Brain Research.

[54]  H. Meziane,et al.  Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. , 1999, Behavioral neuroscience.

[55]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[56]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.

[57]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[58]  T. Nabeshima,et al.  Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. , 1999, European journal of pharmacology.

[59]  D. Linden,et al.  Synaptic Transmission and Hippocampal Long-Term Potentiation in Transgenic Mice Expressing FAD-Linked Presenilin 1 , 1999, Neurobiology of Disease.

[60]  W. K. Cullen,et al.  Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. , 1997, Neuroreport.

[61]  H. Tanila,et al.  Hippocampal Aβ42 Levels Correlate with Spatial Memory Deficit in APP and PS1 Double Transgenic Mice , 2002, Neurobiology of Disease.

[62]  George A. Carlson,et al.  The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[63]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[64]  B. Yee,et al.  Behavioral and neurochemical characterization of transgenic mice carrying the human presenilin-1 gene with or without the leucine-to-proline mutation at codon 235 , 2003, Experimental Neurology.

[65]  R. Malinow,et al.  Enhanced Synaptic Potentiation in Transgenic Mice Expressing presenilin 1 Familial Alzheimer's Disease Mutation Is Normalized with a Benzodiazepine , 2000, Neurobiology of Disease.

[66]  W. K. Cullen,et al.  Block of LTP in rat hippocampus in vivo by β‐amyloid precursor protein fragments , 1997 .

[67]  S. Younkin,et al.  The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[68]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[69]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[70]  K. Duff,et al.  Behavioral Changes in Transgenic Mice Expressing Both Amyloid Precursor Protein and Presenilin-1 Mutations: Lack of Association with Amyloid Deposits , 1999, Behavior genetics.

[71]  T. Iwatsubo,et al.  Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43) , 1994, Neuron.

[72]  O. Arancio,et al.  Receptor protein tyrosine phosphatase α is essential for hippocampal neuronal migration and long‐term potentiation , 2003 .

[73]  T. Priestley,et al.  Long-Term Potentiation Is Increased in the CA1 Area of the Hippocampus of APPswe/ind CRND8 Mice , 2002, Neurobiology of Disease.

[74]  C. Stevens,et al.  Presynaptic mechanism for long-term potentiation in the hippocampus , 1990, Nature.

[75]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.